Characterization of the pathogenic α-Synuclein variant p.V15A in Parkinson´s disease
Objective: To investigate functional alterations of the p.V15A variant in alpha-Synuclein (α-Syn) in Parkinson's disease (PD). Background: PD is marked by the loss of dopaminergic…The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease
Objective: The aim of this study is to investigate the contribution of the glymphatic system to the pathophysiology of Parkinson's disease (PD). Background: Neurotoxicity of…PASADENA 1-year open-label extension
Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…An SNCA triplication in a Kazakhstani patient with young-onset Parkinson’s disease
Objective: To report a patient with Parkinson’s disease (PD) from Kazakhstan with a rare structural defect in the SNCA gene. Background: Little is known about…Baseline characteristics for patients with multiple system atrophy entering a randomized, controlled study of the anti-α-synuclein monoclonal antibody Lu AF82422
Objective: Report baseline characteristics for patients with multiple system atrophy (MSA) entering a study to assess the safety and efficacy of alpha-synuclein (α-syn) monoclonal antibody…Potential role of Alpha-synuclein levels in Platelets in GBA-related PD
Objective: Identification of a blood biomarker to predict PD diagnosis or to monitor the disease progression. Background: Previous evidence suggests differences in systemic alpha-synuclein levels…Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.
Objective: To conduct a case-control study in single, comprehensive movement disorder center in Seoul. Background: Parkinson’s disease (PD) is the second most common neurodegenerative disease…Proof-of-concept clinical trial: Prevent cognitive decline in GBA-associated Parkinson’s Disease
Objective: To prevent cognitive decline in GBA-associated Parkinson’s Disease (PD). Background: Dementia represents a key milestone in the course of PD with limited effective treatments…Elevated plasma CREG1 levels are linked to a lower risk of Parkinson’s disease
Objective: The purpose of this study is to assess the causal associations between plasma cellular repressor of E1A-stimulated genes 1 (CREG1) levels and the risk…Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis
Objective: In this study, we intended to use network meta-analysis to compare the diagnostic performances of different CSF biomarkers in the diagnosis and differential diagnosis…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 60
- Next Page »